Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Hypertension 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms 1Non-alcoholic Fatty Liver Disease 1Lymphoma, Follicular 1Lymphoma 1Hematologic Neoplasms 1Dyspnea 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 22Trastuzumab 16Paclitaxel 15Radiotherapy 13Docetaxel 13Capecitabine 11Doxorubicin 10Taxes 9Lapatinib 9Carboplatin 8Tamoxifen 7Immunohistochemistry 7Biopsy 7Albumin-Bound Paclitaxel 7Magnetic Resonance Spectroscopy 6Fluorodeoxyglucose F18 6Chemotherapy, Adjuvant 6Immunoenzyme Techniques 5Gemcitabine 5Flow Cytometry 5Bevacizumab 5sargramostim 4Vinorelbine 4Letrozole 4Irinotecan 4Granulocyte-Macrophage Colony-Stimulating Factor 4Filgrastim 4Everolimus 4Erlotinib Hydrochloride 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms, Male × Lisinopril × Clear all
NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡